Flputnam Investment Management Co. Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Flputnam Investment Management Co. reduced its stake in Regeneron Pharmaceuticals by 80%, selling 5,992 shares, leaving them with 1,501 shares valued at $952,000.
• Regeneron Pharmaceuticals reported $12.89 EPS in its latest quarter, outperforming expectations of $8.43, with revenues reaching $3.68 billion, up 3.6% year-over-year.
• The company announced a quarterly dividend of $0.88 per share, reflecting an annualized yield of 0.6%, with a dividend payout ratio of 8.87%.

Flputnam Investment Management Co. cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 80.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,501 shares of the biopharmaceutical company's stock after selling 5,992 shares during the period. Flputnam Investment Management Co.'s holdings in Regeneron Pharmaceuticals were worth $952,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after purchasing an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Regeneron Pharmaceuticals by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after purchasing an additional 89,579 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after purchasing an additional 174,056 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Regeneron Pharmaceuticals by 30.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after purchasing an additional 226,952 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on REGN shares. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Citigroup reaffirmed a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Morgan Stanley reaffirmed an "overweight" rating and set a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Raymond James Financial raised shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Trading Up 1.1%

Shares of NASDAQ REGN traded up $6.16 during midday trading on Friday, hitting $573.38. 959,753 shares of the company traded hands, compared to its average volume of 949,804. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,170.58. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock has a 50-day moving average price of $562.59 and a 200 day moving average price of $584.62. The firm has a market cap of $60.77 billion, a P/E ratio of 14.45, a P/E/G ratio of 1.90 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the previous year, the company earned $11.56 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.